Leerink Partnrs Has Bullish Forecast for IDXX Q2 Earnings

IDEXX Laboratories, Inc. (NASDAQ:IDXX) – Analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for IDEXX Laboratories in a report released on Thursday, July 17th. Leerink Partnrs analyst D. Clark now anticipates that the company will post earnings per share of $3.31 for the quarter, up from their prior estimate of $3.22. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $11.93 per share. Leerink Partnrs also issued estimates for IDEXX Laboratories’ Q3 2025 earnings at $3.13 EPS, Q4 2025 earnings at $2.91 EPS, FY2025 earnings at $12.31 EPS, FY2026 earnings at $13.89 EPS, FY2027 earnings at $15.65 EPS and FY2028 earnings at $17.47 EPS.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analysts’ expectations of $998.25 million. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The business’s revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.71 EPS.

Several other analysts have also issued reports on the stock. Stifel Nicolaus increased their price target on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the stock a “hold” rating in a research report on Wednesday, July 2nd. Leerink Partners upped their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, July 12th. Jefferies Financial Group started coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They set a “buy” rating and a $625.00 target price for the company. Finally, Morgan Stanley raised their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a research note on Monday, May 5th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $560.33.

IDEXX Laboratories Stock Down 0.8%

Shares of NASDAQ IDXX opened at $514.61 on Friday. The stock has a market capitalization of $41.38 billion, a P/E ratio of 47.56, a PEG ratio of 3.77 and a beta of 1.54. The stock’s fifty day moving average is $523.58 and its 200 day moving average is $462.69. IDEXX Laboratories has a 52 week low of $356.14 and a 52 week high of $549.52. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16.

Institutional Investors Weigh In On IDEXX Laboratories

Institutional investors have recently added to or reduced their stakes in the business. Opal Wealth Advisors LLC acquired a new position in shares of IDEXX Laboratories during the second quarter worth $29,000. MorganRosel Wealth Management LLC bought a new position in IDEXX Laboratories during the 1st quarter worth $26,000. Hurley Capital LLC acquired a new position in IDEXX Laboratories during the 4th quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after buying an additional 30 shares during the last quarter. Finally, Colonial Trust Co SC grew its position in shares of IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company’s stock valued at $35,000 after buying an additional 39 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of the company’s stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the transaction, the director owned 1,801 shares of the company’s stock, valued at $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.